Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Soleno Therapeutics (NASDAQ: SLNO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation. Analyst Ratings This is a breakdown of current
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our fourth quarter performance capped off a truly transformative 2025. Recorlev® delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year,” said John Shannon, Chief Executive Officer. “When combined with the stellar contribution.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the transaction, the insider owned 1,308,103 shares in the company,
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 181,550 shares of its common stock to 50 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equit.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $7.31, but opened at $7.89. Xeris Biopharma shares last traded at $8.0450, with a volume of 1,581,185 shares changing hands. Analysts Set New Price Targets XERS has been the subject of
It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock.
Squarepoint Ops LLC boosted its position in Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) by 1,679.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 284,567 shares of the company's stock after buying an additional 268,572 shares
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and ARS Pharmaceuticals (NASDAQ: SPRY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Analyst Recommendations This is a breakdown of
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.'s U.S. patent application covering XP-8121, one of its novel product candidates. The Notice of Allowance indica.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the
Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John Shannon - CEO & Director Steven Pieper - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 Earnings Conference Call.
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Xeris Biopharma (XERS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.06 per share a year ago.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. “We delivered another record-breaking quarter, driven by increased patient demand across all three products,” said John Shannon, Chief Executive Officer. “Total product revenue grew 4.
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the.
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 382,975 shares of its common stock to 40 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equit.